Effects of Empagliflozin on vascular and skeletal mineralization in Hyperlipidemic mice

By sjmartinez • May 2, 2024

Kalanski S, Pradhan S, Hon A, Xia Y, Safvati N, Rivera JC, Lu M, Demer LL, Tintut Y. Effects of Empagliflozin on vascular and skeletal mineralization in Hyperlipidemic mice. Vascul Pharmacol. 2024 Apr 29:107376. doi: 10.1016/j.vph.2024.107376. Epub ahead of print. PMID: 38692418.

Tags: Cardiology/Epi, empagliflozin, hyperlipidemia, Publications, SGLT2

Mid- to Late-Life Traditional Cardiovascular Risk Factor Exposure and Zero Coronary Artery Calcium: The ARIC (Atherosclerosis Risk in Communities) Study

Wang FM, Ballew SH, Folsom AR, Wagenknecht LE, Howard CM, Coresh J, Budoff MJ, Blaha MJ, Matsushita K. Mid- to Late-Life Traditional Cardiovascular Risk Factor[...]

South Asians and cardiometabolic health: A framework for comprehensive care for the individual, community, and population – An American society for preventive cardiology clinical practice statement

Rohatgi A, Anand SS, Gadgil M, Gujral UP, Jain SS, Javed Z, Jha M, Joshi PH, Manubolu VS, Nasir K, Natarajan P, Pagidipati N, Palaniappan[...]

Treated HIV infection is not associated with carotid vascular inflammation or plaque progression as assessed by dynamic contrast magnetic resonance imaging

Shakil S, Chen D, Isquith D, Sapp J, Pommier I, Chu B, Guo Y, Canton G, Balu N, Yuan C, Hatsukami T, Maynard C, Zhao[...]